| Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas K Shoji, K Oda, T Kashiyama, Y Ikeda, S Nakagawa, K Sone, Y Miyamoto, ... PloS one 7 (5), e37431, 2012 | 96 | 2012 |
| The anti-malarial chloroquine suppresses proliferation and overcomes cisplatin resistance of endometrial cancer cells via autophagy inhibition T Fukuda, K Oda, O Wada-Hiraike, K Sone, K Inaba, Y Ikeda, A Miyasaka, ... Gynecologic oncology 137 (3), 538-545, 2015 | 83 | 2015 |
| Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells A Miyasaka, K Oda, Y Ikeda, O Wada-Hiraike, T Kashiyama, A Enomoto, ... BMC cancer 14, 1-10, 2014 | 67 | 2014 |
| Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing M Jang, PY Yew, K Hasegawa, Y Ikeda, K Fujiwara, GF Fleming, ... Oncoimmunology 4 (11), e1030561, 2015 | 58 | 2015 |
| Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal … S Murayama-Hosokawa, K Oda, S Nakagawa, S Ishikawa, S Yamamoto, ... Oncogene 29 (13), 1897-1908, 2010 | 57 | 2010 |
| Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423 T Kashiyama, K Oda, Y Ikeda, Y Shiose, Y Hirota, K Inaba, C Makii, ... PloS one 9 (2), e87220, 2014 | 55 | 2014 |
| Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report K Shoji, K Oda, S Nakagawa, K Kawana, T Yasugi, Y Ikeda, Y Takazawa, ... Medical Oncology 28, 771-774, 2011 | 30 | 2011 |
| Minimization of curative surgery for treatment of early cervical cancer: a review T Arimoto, K Kawana, K Adachi, Y Ikeda, K Nagasaka, T Tsuruga, ... Japanese Journal of Clinical Oncology 45 (7), 611-616, 2015 | 29 | 2015 |
| Multifunctional transcription factor TFII-I is an activator of BRCA1 function M Tanikawa, O Wada-Hiraike, S Nakagawa, A Shirane, H Hiraike, ... British journal of cancer 104 (8), 1349-1355, 2011 | 29 | 2011 |
| Effect of lymphovascular space invasion on survival of stage I epithelial ovarian cancer K Matsuo, K Yoshino, K Hiramatsu, C Banzai, K Hasegawa, M Yasuda, ... Obstetrics & Gynecology 123 (5), 957-965, 2014 | 26 | 2014 |
| Cyclin D1 harboring the T286I mutation promotes oncogenic activation in endometrial cancer Y Ikeda, K Oda, O Hiraike-Wada, T Koso, A Miyasaka, T Kashiyama, ... Oncology Reports 30 (2), 584-588, 2013 | 23 | 2013 |
| Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion K Matsuo, K Yoshino, K Hasegawa, R Murakami, Y Ikeda, S Adachi, ... Gynecologic oncology 136 (2), 198-204, 2015 | 22 | 2015 |
| Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin M Takano, Y Ikeda, K Kudoh, T Kita, N Sasaki, Y Kikuchi Journal of Obstetrics and Gynaecology Research 39 (4), 872-875, 2013 | 18 | 2013 |
| Genome-wide single nucleotide polymorphism arrays as a diagnostic tool in patients with synchronous endometrial and ovarian cancer Y Ikeda, K Oda, S Nakagawa, S Murayama-Hosokawa, S Yamamoto, ... International Journal of Gynecologic Cancer 22 (5), 2012 | 17 | 2012 |
| Role of multifunctional transcription factor TFII-I and putative tumour suppressor DBC1 in cell cycle and DNA double strand damage repair M Tanikawa, O Wada-Hiraike, N Yoshizawa-Sugata, A Shirane, M Hirano, ... British journal of cancer 109 (12), 3042-3048, 2013 | 16 | 2013 |
| Weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with recurrent and refractory ovarian cancer: a preliminary result of 19 cases Y Ikeda, M Takano, K Oda, H Kouta, T Goto, K Kudoh, N Sasaki, T Kita, ... International Journal of Gynecologic Cancer 23 (2), 2013 | 16 | 2013 |
| Primary vaginal calculus in a middle-aged woman with mental and physical disabilities Y Ikeda, K Oda, N Matsuzawa, K Shimizu International urogynecology journal 24, 1229-1231, 2013 | 15 | 2013 |
| mTOR signaling in endometrial cancer: from a molecular and therapeutic point of view K Oda, Y Ikeda, K Kawana, Y Osuga, T Fujii Current Obstetrics and Gynecology Reports 4, 1-10, 2015 | 12 | 2015 |
| Positive peritoneal cytology at interval surgery is a poor prognostic factor in patients with stage T3c advanced ovarian carcinoma: a retrospective study K Nagasaka, K Kawana, K Tomio, T Tsuruga, M Mori‐Uchino, S Miura, ... Journal of Obstetrics and Gynaecology Research 41 (5), 755-762, 2015 | 10 | 2015 |
| Synchronous mucinous metaplasia and neoplasia of the female genital tract with external urethral meatus neoplasm: A case report Y Ikeda, M Yasuda, T Kato, Y Yano, A Kurosaki, K Hasegawa Gynecologic Oncology Reports 12, 27, 2015 | 9 | 2015 |
Katsutoshi Oda東京大学大学院医学系研究科 統合ゲノム学Verified email at umin.ac.jp
Katsutoshi Oda東京大学大学院医学系研究科 統合ゲノム学Verified email at umin.ac.jp